Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hasmann

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Journal of Cancer Research and Clinical Oncology|April 3, 2009
Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivoMichael Pohl, I Stricker, A Schoeneck, et al.
Oncogenesis|April 5, 2013
Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugsF Henjes, C Bender, S von der Heyde, et al.
British Journal of Cancer|May 3, 2012
Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancerA H Sims, A J M Zweemer, Y Nagumo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2013
Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industryR Bartsch, S Frings, M Marty, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Journal of Cancer Research and Clinical Oncology|April 3, 2009
Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivoMichael Pohl, I Stricker, A Schoeneck, et al.
Oncogenesis|April 5, 2013
Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugsF Henjes, C Bender, S von der Heyde, et al.
British Journal of Cancer|May 3, 2012
Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancerA H Sims, A J M Zweemer, Y Nagumo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2013
Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industryR Bartsch, S Frings, M Marty, et al.
Pageof 2